Category Archives: Company Profiles

Q Therapeutics’ and Invitrogen’s Symbiotic Relationship

Posted on February 25, 2008 by jrowley

Q Therapeutics, a cell therapy company focusing on neural applications, recently announced a $15M series B financing that included funding from multiple venture capital (VC) groups as well as biotech tools provider Invitrogen. Q’s lead product, Q-Cells™, is an allogeneic … Continue reading →

Posted in adult stem cell, Bioprocessing, Clinical Trials, Company Profiles, Manufacturing, MS, Neural Repair, Q Therapeutics, Regenerative Medicine, stem cells | Tagged , , , | 2 Comments

Cytori Announces Progress in Cardiac Regeneration Clinical Studies

Posted on February 1, 2008 by jrowley

Cytori Therapeutics announced that they have enrolled their first two patients in an acute myocardial infarction clinical trial using adipose-derived cells prepared using their Celution™ device. The Celution™ device is an automated, tissue processing unit that isolates cells from adipose … Continue reading →

Posted in adult stem cell, autologous, Bioprocessing, cardiac regeneration, cell delivery, Clinical Trials, Company Profiles, Cytori, Device-centric cell therapies, patient specific cell therapy, personalized medicine, Regenerative Medicine, stem cells | Leave a comment

Tengion Pioneers Autologous Tissue Engineered Regenerative Medicine Products

Posted on January 29, 2008 by jrowley

You have to hand it to Tengion, they are trying to tackle one of the largest challenges I can think of: producing tissue engineered organs and tissues from a patients own cells in unrelated indications (bladder, blood vessel, and kidney). … Continue reading →

Posted in autologous, Biomaterials, Bioprocessing, Clinical Trials, combination products, Company Profiles, JNJ, patient specific cell therapy, personalized medicine, Regenerative Medicine, Tengion, tissue engineered product, vascular regeneration | Tagged , , | 3 Comments

Pervasis Advances Tissue Engineered Products for Vascular Health

Posted on January 22, 2008 by jrowley

Pervasis Therapeutics announced that they have raised $9.75M to further develop their allogenic tissue engineered endothelial cell (EC) product for vascular health indications. Their Vascugel product is comprised of ECs grown in 3D collagen sponges that are implanted externally on … Continue reading →

Posted in Biomaterials, Bioprocessing, cell delivery, Clinical Trials, combination products, Company Profiles, Manufacturing, Pervasis, Regenerative Medicine, tissue engineered product, vascular regeneration | Tagged , , , , , | 1 Comment

Biomimetics Therapeutics Expands into New Markets with Innovative GEM OS Combination Device

Posted on January 8, 2008 by shsiong

by Susan Hsiong, PhD Biomimetics Therapeutics, Inc. (Franklin, TN), a company which develops drug-device combination products for orthopedic applications, recently announced positive results from its Canadian clinical study evaluating its GEM OS®1 Bone Graft for the open surgical treatment of … Continue reading →

Posted in Biomaterials, biomimetics therapeutics, bone regeneration, combination products, Company Profiles, controlled release, Medtronic, Regenerative Medicine | Tagged , , , , , , , , | 3 Comments

Chinese CRO WuXi Pharmatech Acquires Apptec Laboratory Services

Posted on January 7, 2008 by jrowley

WuXi (pronounced Woo-See) Pharmatech, a contract research organization (CRO) based in China, announced the acquisition of MN-based Apptec Laboratory Services. WuXi acquired Apptec to gain an immediate US footprint, better access to the US market, and important biologics expertise to … Continue reading →

Posted in Apptec, BD, Bioprocessing, business models, Company Profiles, Invitrogen, JNJ, Lonza, Manufacturing, Regenerative Medicine, WuXi Pharmatech | 1 Comment